Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.78 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.76 |
| ▸ | MMP2 | P08253 | 1/20 | 0.67 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.64 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.63 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5698697 | 0.95 | PTGS2 (0.88) | PTGS2CYP2C9PTGS1PDPK1CHRNA7 | |
| SCHEMBL5698730 | 0.92 | CYP2C9 (0.85) | PTGS2CYP2C9PTGS1MMP2PDPK1 | |
| SCHEMBL8118945 | 0.91 | PTGS2 (0.73) | PTGS2CYP2C9PTGS1MMP2PDPK1 | |
| SCHEMBL8126342 | 0.91 | PTGS2 (0.73) | PTGS2CYP2C9PTGS1MMP2PDPK1 | |
| SCHEMBL8112204 | 0.90 | PTGS2 (0.80) | PTGS2CYP2C9PTGS1PDPK1CHRNA7 | |
| SCHEMBL8112778 | 0.90 | PTGS2 (0.80) | PTGS2CYP2C9PTGS1PDPK1CHRNA7 | |
| SCHEMBL6906481 | 0.89 | PTGS2 (0.79) | PTGS2CYP2C9PTGS1MMP2PDPK1 | |
| SCHEMBL8114069 | 0.89 | PTGS2 (0.79) | PTGS2CYP2C9PTGS1MMP2PDPK1 | |
| SCHEMBL8112050 | 0.89 | PTGS2 (0.79) | PTGS2CYP2C9PTGS1PDPK1CHRNA7 | |
| SCHEMBL8111712 | 0.89 | PTGS2 (0.79) | PTGS2CYP2C9PTGS1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 420 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1332661-C | Methods of treating and preventing neoplasia using cyclooxygenase-2 inhibitors | SEARLE & CO (US) | 2007-08-22 | — | — | CN | claimed |
| CN-1767835-A | Compositions comprising cyclooxygenase-2 selective inhibitors and glucosamine for the treatment and prevention of pain and inflammation | PHARMACIA CORP (US) | 2006-05-03 | — | — | CN | claimed |
| EP-0843549-B1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4 HYDROLASE INHIBITOR | SEARLE & CO (US) | 2006-04-12 | — | — | EP | claimed |
| CN-1697654-A | Use of COx-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections | UPJOHN CO (US) | 2005-11-16 | — | — | CN | claimed |
| EP-0833622-B8 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | SEARLE & CO (US) | 2005-10-12 | — | — | EP | claimed |
| CN-1660083-A | Method of using benzenesulphoamides that are cyclooxygenase-2-inhibitors in the treatment and prevention of neoplasia | G D SIORL & CO (US) | 2005-08-31 | — | — | CN | claimed |
| EP-0833622-B1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | SEARLE & CO (US) | 2005-08-10 | — | — | EP | claimed |
| EP-1539142-A2 | USE OF AN AMYLOID BETA VACCINATION IN COMBINATION WITH A SELECTIVE COX-2 INHIBITOR FOR THE TREATMENT OF ALZHEIMER S DISEASE | Pharmacia Corporation (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1536863-A1 | USE OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THROMBOLYTIC AGENTS FOR THE TREATMENT OR PREVENTION OF A VASO-OCCLUSIVE EVENT | Pharmacia Corporation (US) | 2005-06-08 | — | — | EP | claimed |
| EP-1509224-A1 | METHODS USING A COMBINATION OF A 3-HETEROARYL-2-INDOLINONE AND A CYCLOOXYGENASE-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA | Pharmacia Corporation (US) | 2005-03-02 | — | — | EP | claimed |
| CN-1247470-A | Methods of using cyclooxygenase-2 inhibitors as anti-angiogenic agents | SEARLE & CO (US) | 2000-03-15 | — | — | CN | claimed |
| CN-1244122-A | Methods of treating and preventing neoplasia using cyclooxygenase-2 inhibitors | SEARLE & CO (US) | 2000-02-09 | — | — | CN | claimed |
| EP-0941080-A2 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS AS ANTI-ANGIOGENIC AGENTS | G.D. SEARLE & CO. (US) | 1999-09-15 | — | — | EP | claimed |
| WO-1998022101-A2 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS AS ANTI-ANGIOGENIC AGENTS | G.D. SEARLE & CO. (US) | 1998-05-28 | — | — | WO | claimed |
| EP-0843549-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4? HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0833622-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | G.D. SEARLE & CO. (US) | 1998-04-08 | — | — | EP | claimed |
| EP-0833664-A1 | COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B 4? RECEPTOR ANTAGONIST FOR THE TREATMENT OF INFLAMMATIONS | G.D. SEARLE & CO. (US) | 1998-04-08 | — | — | EP | claimed |
| WO-1996041645-A1 | COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B4 RECEPTOR ANTAGONIST FOR THE TREATMENT OF INFLAMMATIONS | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
| WO-1996041626-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
| WO-1996041625-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A4 HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |